Follistatin-like 3 (FSTL-3), also known as Follistatin-related Accurate Gene (FLRG) and Follistatin-related protein (FSRP), is a 30-35 kDa secreted glycoprotein. FSTL-3 encodes a novel secreted glycoprotein that is highly homologous to follistatin and binds activins and bone morphogenetic proteins, members of the TGF beta superfamily of growth/differentiation factors. FSTL-3 protein inhibits activin-induced and bone morphogenetic protein-2-induced transcriptional responses in a dosedependent manner, and its mRNA is abundantly expressed in human placenta, trophoblast, heart, uterus, ovary, testis and adrenal gland. Mature human FSTL-3 consists of an Activin and Myostatin binding N-terminal domain, two Follistatin-like domains, and two Kazal-like domains. BMP-2, -6, and -7 do not compete for Activin A binding, and FSTL-3 binds only weakly to Activin B. Unlike Follistatin, FSTL-3 does not contain a heparin-binding domain and does not interact with heparin sulfate proteoglycans. FSTL-3 has been studied in regulation of energy balance and metabolism, gestational diabetes, preeclampsia, and promotor of tumor cell proliferation.
The Ansh Labs’ Follistatin-like 3 (FSTL-3) ELISA is a quantitative three-step sandwich type immunoassay. FSTL-3, also known as Follistatin-related Gene (FLRG) and Follistatin-related protein (FSRP), has been studied in regulation of energy balance and metabolism, gestational diabetes, preeclampsia, and promotor of tumor cell proliferation.
Research Use Only within the United States. Ansh Labs is an FDA registered manufacturer of diagnostic test kits, antibodies, antigens, and proteins.